Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.64 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.44 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.44 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 3/20 | 0.40 |
| ▸ | TNFRSF1A | P19438 | 3/20 | 0.40 |
| ▸ | MAP3K9 | P80192 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6944361 | 0.94 | MAP2K1 (0.57) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6035416 | 0.90 | MAP2K1 (0.60) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6946551 | 0.89 | MAP2K1 (0.52) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6946808 | 0.88 | MAP2K1 (0.51) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6949973 | 0.87 | MAP2K1 (0.50) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6947427 | 0.86 | MAP2K1 (0.48) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6946582 | 0.85 | MAP2K1 (0.48) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6950685 | 0.85 | MAP2K1 (0.54) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6948744 | 0.85 | MAP2K1 (0.54) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6944261 | 0.85 | MAP2K1 (0.49) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0993437-B1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2006-11-08 | — | — | EP | claimed |
| EP-1202724-B1 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER LAMBERT CO (US) | 2003-10-01 | — | — | EP | claimed |
| US-20030149015-A1 | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives | BARRETT STEPHEN DOUGLAS (US) | 2003-08-07 | — | — | US | claimed |
| JP-2003504401-A | — | — | 2003-02-04 | — | — | JP | claimed |
| JP-2003504399-A | — | — | 2003-02-04 | — | — | JP | claimed |
| JP-2003504400-A | — | — | 2003-02-04 | — | — | JP | claimed |
| US-6506798-B1 | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors | WARNER-LAMBERT COMPANY | 2003-01-14 | — | — | US | claimed |
| US-6492363-B2 | FOR THERAPY OF CANCER AND OTHER PROLIFERATIVE DISEASES SUCH AS INFLAMMATION, PSORIASIS AND RESTENOSIS, AS WELL AS STROKE, HEART FAILURE, AND IMMUNODEFICIENCY DISORDERS | WARNER-LAMBERT COMPANY | 2002-12-10 | — | — | US | claimed |
| EP-1202724-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | claimed |
| EP-1202732-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-08 | — | — | EP | claimed |
| EP-1202726-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-08 | — | — | EP | claimed |
| US-20020022647-A1 | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives | BARRETT STEPHEN DOUGLAS (US) | 2002-02-21 | — | — | US | claimed |
| EP-1144362-A1 | 4-ARYLAMINO, 4-ARYLOXY, AND 4-ARYLTHIO DIARYLAMINES AND DERIVATIVES THEREOF AS SELECTIVE MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2001005393-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| WO-2001005392-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| WO-2001005391-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| WO-2000041994-A1 | 4-ARYLAMINO, 4-ARYLOXY, AND 4-ARYLTHIO DIARYLAMINES AND DERIVATIVES THEREOF AS SELECTIVE MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | claimed |
| EP-0993437-A1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-04-19 | — | — | EP | claimed |
| WO-1999001421-A1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-01-14 | — | — | WO | claimed |
| EP-0993437-B1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1202724-B1 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER LAMBERT CO (US) | 2003-10-01 | — | — | EP | disclosed |
| US-6506798-B1 | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors | WARNER-LAMBERT COMPANY | 2003-01-14 | — | — | US | disclosed |
| EP-1202724-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1202732-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1144362-A1 | 4-ARYLAMINO, 4-ARYLOXY, AND 4-ARYLTHIO DIARYLAMINES AND DERIVATIVES THEREOF AS SELECTIVE MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001005393-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005391-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| JP-2000204068-A | DIARYLAMINE | WARNER LAMBERT CO | 2000-07-25 | — | — | JP | disclosed |
| WO-2000041994-A1 | 4-ARYLAMINO, 4-ARYLOXY, AND 4-ARYLTHIO DIARYLAMINES AND DERIVATIVES THEREOF AS SELECTIVE MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000041994-A1 | 4-ARYLAMINO, 4-ARYLOXY, AND 4-ARYLTHIO DIARYLAMINES AND DERIVATIVES THEREOF AS SELECTIVE MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149015-A1 | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives | BCOR, BCL6, CBR1 | MAP2K1 349/4885MAP2K2 161/4885RAF1 89/4885 |
| US-20020022647-A1 | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives | BCOR, BCL6, CBR1 | MAP2K1 349/4885MAP2K2 161/4885RAF1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.